Business Context and Reporting Period
Company: Lineage Cell Therapeutics, Inc. (LCTX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A clinical-stage biotechnology company developing allogeneic ("off-the-shelf") cell therapies for neurological and ophthalmic conditions. Key programs include OpRegen (in collaboration with Roche/Genentech for geographic atrophy) and OPC1 (for spinal cord injury). Manufacturing is centralized at a facility in Jerusalem, Israel.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2025 |
Six Months Ended June 30, 2024 |
|---|---|---|---|
| Total Revenues | $2,765 | $4,267 | $2,852 |
| Net Loss (Attributable to Lineage) | $(30,464) | $(34,603) | $(12,302) |
| Loss from Operations | $(19,780) | $(26,285) | $(12,528) |
| Net Cash Used in Operating Activities | N/A | $(10,425) | $(10,959) |
| Cash, Cash Equivalents & Marketable Securities | $42,288 (as of June 30, 2025) | $42,288 (as of June 30, 2025) | $35,992 (as of June 30, 2024) |
| Warrant Liabilities | $18,801 | $18,801 | $0 |
Note: Cash and cash equivalents were $42,271 thousand; marketable securities were $17 thousand as of June 30, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 96% ($1.4M) for the quarter and 50% ($1.4M) for the six months compared to the prior year periods. This was driven primarily by collaboration revenues from the Roche Agreement, which increased due to progress on performance obligations and the recognition of remaining deferred revenue from a terminated agreement with Immunomic Therapeutics.
- Significant Impairment Charge: The company recorded a non-cash impairment charge of $14.8 million related to the abandonment of the VAC platform (an intangible asset from the Asterias Merger). This charge was the primary driver of the increased operating loss.
- Warrant Liability Volatility: A non-cash loss of $12.7 million (quarter) and $10.4 million (six months) was recorded due to the change in fair value of warrant liabilities issued in the November 2024 Registered Direct Offering (RDO). This was driven by an increase in the company's stock price.
- Foreign Currency Gains: The company recognized a foreign currency transaction gain of $1.7 million for the quarter and $1.4 million for the six months, reversing prior year losses, due to the strengthening of the Israeli New Shekel and Singapore Dollar against the U.S. Dollar.
Guidance, Outlook, and Risks
- Clinical Progress:
- OpRegen: Positive 36-month visual acuity results were presented in June 2025, showing durable gains in Best Corrected Visual Acuity (BCVA) for patients with extensive cell therapy coverage. The program holds RMAT designation from the FDA.
- OPC1: The DOSED study, evaluating a novel delivery device for spinal cord injury, treated its first chronic SCI patient in July 2025.
- Liquidity and Capital: As of June 30, 2025, the company held approximately $42.3 million in cash and marketable securities. Management believes this is sufficient to fund operations for at least 12 months. The company has $39.97 million remaining available under its At-The-Market (ATM) offering program.
- Key Risks:
- Geopolitical Conflict: All manufacturing is conducted in Jerusalem, Israel. While operations have not been materially impacted to date, the ongoing regional conflict poses risks to workforce availability, facility safety, and supply chain continuity.
- Capital Requirements: The company expects to continue incurring significant losses and will require additional capital to fund clinical trials and operations.
- Manufacturing Scalability: Risks exist regarding the ability to consistently manufacture clinical quantities at a cost-effective scale.
Investor Verification Checklist
- Impairment Details: Verify the specific rationale and accounting treatment for the $14.8 million impairment of the VAC platform intangible asset.
- Warrant Liability Exposure: Monitor the fair value of the $18.8 million warrant liability, as fluctuations in stock price will continue to impact reported net loss without affecting cash flow.
- Israel Operations Status: Confirm the current operational status of the Jerusalem manufacturing facility and any potential disruptions due to the regional conflict.
- Roche Collaboration Milestones: Track progress on the Roche Agreement performance obligations, as this is the primary revenue driver and source of future milestone payments.
- Cash Burn Rate: Assess the sustainability of the current cash position ($42.3M) against the projected operating losses and the timeline for potential future capital raises.